文献速递免疫规划

重组刺突蛋白疫苗联合不同作用方式佐剂可诱导针对SARS-CoV-2的保护性免疫

Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
PubMed 文献 · Vaccine · 2023-08-25

研究在叙利亚仓鼠和小鼠模型中评估重组刺突(S)蛋白疫苗联合不同佐剂(Alhydrogel、Quil-A、AS03样佐剂)的免疫原性和保护效果。结果表明,佐剂疫苗可诱导抗S受体结合域(RBD)血清IgG和中和抗体,降低呼吸道器官病毒复制、体重丢失和肺部炎症;对变异株结合抗体和T细胞反应与野生型相当,但中和抗体滴度明显下降。

要点

  • Alhydrogel或Quil-A佐剂S蛋白疫苗在仓鼠中诱导抗RBD IgG和中和抗体,降低病毒复制和体重丢失。
  • Alhydrogel、Quil-A或AS03样佐剂在小鼠中诱导的中和抗体滴度显著高于无佐剂疫苗。
  • 野生型S疫苗接种仓鼠在Omicron XBB攻击后,Alhydrogel或AS03降低第3天肺部病毒滴度,Quil-A组体重丢失更少。

核心结论

  • 重组疫苗联合不同佐剂可能通过诱导多种免疫反应环节成为对抗新变异病毒的有前景的策略。

研究设计与样本

  • 研究在叙利亚仓鼠模型和小鼠模型中评估重组S蛋白疫苗联合Alhydrogel、Quil-A或AS03样佐剂的免疫原性和保护效果,并开展Omicron XBB攻击实验。

主要发现

  • 在叙利亚仓鼠模型中,Alhydrogel或QS-21样佐剂Quil-A佐剂的S蛋白疫苗有效诱导抗S受体结合域(RBD)血清IgG和中和抗体滴度,导致呼吸道器官中SARS-CoV-2复制显著降低,并减少病毒攻击后的体重丢失。
  • 病毒攻击后的严重肺部炎症也被疫苗接种强烈抑制。
  • 在小鼠中,Alhydrogel、Quil-A或AS03样佐剂S蛋白疫苗诱导的中和抗体滴度显著高于无佐剂疫苗。
  • 尽管小鼠中针对变异病毒B.1.351和B.1.617.2的中和抗体滴度明显下降,但针对变异S蛋白的结合抗体水平与针对野生型S蛋白相当。
  • 免疫小鼠脾细胞体外再刺激后,野生型S或变异S再刺激诱导的Th1或Th2细胞因子水平无显著差异,提示针对变异株的T细胞反应与针对野生型病毒相同。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a glycoprotein, expressed on the virion surface, that mediates infection of host cells by directly interacting with host receptors. As such, it is a reasonable target to neutralize the infectivity of the virus. Here we found that a recombinant S protein vaccine adjuvanted with Alhydrogel or the QS-21-like adjuvant Quil-A effectively induced anti-S receptor binding domain (RBD) serum IgG and neutralizing antibody titers in the Syrian hamster model, resulting in significantly low SARS-CoV-2 replication in respiratory organs and reduced body weight loss upon virus challenge. Severe lung inflammation upon virus challenge was also strongly suppressed by vaccination. We also found that the S protein vaccine adjuvanted with Alhydrogel, Quil-A, or an AS03-like adjuvant elicited significantly higher neutralizing antibody titers in mice than did unadjuvanted vaccine. Although the neutralizing antibody titers against the variant viruses B.1.351 and B.1.617.2 declined markedly in mice immunized with wild-type S protein, the binding antibody levels against the variant S proteins were equivalent to those against wild-type S. When splenocytes from the immunized mice were re-stimulated with the S protein in vitro, the induced Th1 or Th2 cytokine levels were not significantly different upon re-stimulation with wild-type S or variant S, suggesting that the T-cell responses against the variants were the same as those against the wild-type virus. Upon Omicron XBB-challenge in hamsters, wild-type S-vaccination with Alhydrogel or AS03 reduced lung virus titers on Day 3, and the Quil-A adjuvanted group showed less body weight loss, although serum neutralizing antibody titers against XBB were barely detected in vitro. Collectively, recombinant vaccines coupled with different adjuvants may be promising modalities to combat new variant viruses by inducing various arms of the immune response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chiba S, Halfmann PJ, Iida S, et al. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2. Vaccine. 2023. PMID: 37635002. doi:10.1016/j.vaccine.2023.08.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。